Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers. By Roots Analysis
Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.
- A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies, featuring details on immuno-oncology biomarkers and disease indications being investigated, based on trial registration year, phase of development, recruitment status, therapy design and type of cancer therapy.
- An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+), based on a number of relevant parameters, such as year of establishment, size of employee base, location of headquarters, availability status of the test, biomarkers analyzed, application areas, disease indication(s) evaluated, analytical techniques utilized, turnaround time, sample input and others.
- An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups), taking into consideration the supplier power (size of employee base) and specific test related parameters, such as, application area of the test, turnaround time and other key specifications.
- Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio), featuring a brief overview of the company, its financial information (if available), information on biomarker testing related service(s), recent developments and an informed future outlook.
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this https://www.rootsanalysis.com/reports/253/request-sample.html
The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:
- Type of test
- Laboratory Developed Tests (LDTs)
- Companion Diagnostic Tests (CDx)
- Type of disease indication
- Breast cancer
- Blood cancer
- Colon / Colorectal cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Type of cancer biomarker
- TMB
- MSI / MMR
- TILs
- Type of analytical technique
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Others
- Key geographical regions
- North America
- Europe
- Japan
- China
- Australia
The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain:
- Foundation Medicine
- NeoGenomics Laboratories
- Novogene
- Q2 Solutions
- Personal Genome Diagnostics
- Dr Lal PathLabs
- Shenzhen Yuce Biotechnology
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Product Competitiveness Analysis
6. Company Profiles
7. Publication Analysis
8. Innovative Designs for Biomarker-Based Clinical Trials
9. Clinical Trial Analysis
10. Market Forecast
11. Future Growth Opportunities
12. Case Study: Analysis of Needs of Stakeholders in The Companion Diagnostics Industry
13. Case Study: Analysis of Value Chain in the Companion Diagnostics Industry
14. Clinical Research on Cancer Biomarkers: A Big Pharma Perspective
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com